Back to results
US 2025/0154102 A1Published application
Cyclic lipids and methods of use thereof
AssigneeReNAgade Therapeutics Management Inc.
InventorsMuthusamy Jayaraman, Stephen Scully
Life of this patent
Estimating the term…
Abstract
The present disclosure details various lipids, compositions, and/or methods of optimized systems and delivery vehicles for the delivery of nucleic acid sequences, polypeptides or peptides for use in vaccinating against infectious agents.
Claims27
A compound of Formula (CX-II)
- or a pharmaceutically acceptable salt thereof,
- wherein
- Z is selected from the group consisting of a bond,
- each Y is independently selected from the group consisting of
- R1 is —(CH2)1-6N(Ra)2 or —(CH2)1-6OH;
- R2 is optionally substituted C5-C36 alkyl or optionally substituted C5-C36 alkenyl, wherein 2 methylene units of R2 are replaced with —O— to form an acetal within R2, and wherein 1-6 methylene units of R2 are optionally replaced with a group each independently selected from cyclopropylene, —O—, —OC(O)—, and —C(O)O—;
- R2′ is optionally substituted C1-C36 alkyl or optionally substituted C5-C36 alkenyl, wherein 1-6 methylene units of R2′ are optionally replaced with a group each independently selected from cyclopropylene, —O—, —OC(O)—, and —C(O)O—;
- each Ra is independently optionally substituted C1-C6 alkyl;
- or
- two Ra are taken together, with the nitrogen on which they are attached, to form an optionally substituted 4-7 membered heterocyclyl ring;
- m is 0, 1, or 2;
- n is 1 or 2;
- and
- p is 1 or 2.
11 more elements
2-3. (canceled)
7-8. (canceled)
12-54. (canceled)
A compound of table (II) or a pharmaceutically acceptable salt thereof.
57-78. (canceled)
A compound of Formula (CZ-I)
- or a pharmaceutically acceptable salt thereof,
- wherein
- Z is selected from the group consisting of a bond,
- each Y is independently selected from the group consisting of,
- R1 is —(CH2)1-6N(Ra)2;
- each R2 is independently optionally substituted C1-C36 alkyl or optionally substituted C2-C36 alkenyl, wherein 1-6 methylene units of R2 are optionally replaced with a group each independently selected from cyclopropylene, —O—, —OC(O)—, and —C(O)O—;
- each Ra is independently optionally substituted C1-C6 alkyl;
- or
- two Ra are taken together, with the nitrogen on which they are attached, to form an optionally substituted 4-7 membered heterocyclyl ring;
- m is 0, 1, or 2;
- n is 1 or 2;
- and
- p is 1 or 2.
10 more elements
A compound of Formula (CZ-II)
- or a pharmaceutically acceptable salt thereof,
- wherein
- Z is selected from the group consisting of a bond,
- each Y is independently selected from the group consisting of,
- R1 is —(CH2)1-6N(Ra)2;
- each R2 is independently optionally substituted C1-C36 alkyl or optionally substituted C2-C36 alkenyl, wherein 1-6 methylene units of R2 are optionally replaced with a group each independently selected from cyclopropylene, —O—, —OC(O)—, and —C(O)O—;
- each Ra is independently optionally substituted C1-C6 alkyl;
- or
- two Ra are taken together, with the nitrogen on which they are attached, to form an optionally substituted 4-7 membered heterocyclyl ring;
- m is 0, 1, or 2;
- n is 1 or 2;
- and
- p is 1 or 2.
10 more elements
Dependencies are inferred from the claim text.